Science 2 min read

23andMe Pivots From Genomics to Medical Research in new Merger

The personal genomics company 23andMe already raises certain alarms when it comes to biosecurity. But thanks to a new $300-million partnership with GlaxoSmithKline, previous users of the 23andMe ancestry kits might find their information even more vulnerable than before.

The Genomics Firm 23andme is pivoting its business towards medical research thanks to a new merger. | Image By Victor Moussa | Shutterstock

The Genomics Firm 23andme is pivoting its business towards medical research thanks to a new merger. | Image By Victor Moussa | Shutterstock

23andMe just announced a $300 million deal with the British medical firm GlaxoSmithKline, possibly changing the services and goals of the company completely.  

We have written about 23andMe several times over the last year. However, it wasn’t always in the most positive of light regarding cyberbiosecurity.

We already know that companies like 23andMe often sell your genetic data to third parties. Partnering with this new drug company probably means that that information will become further compromised (if it hasn’t been already).

Despite these cyberbiosecurity concerns, the company received a new round of funding to the tune of $300-million USD.

What will one of the leading personal genomics companies do with this cash influx?

image of 23andMe logo, home kit, and welcome letter for article 23andMe Shares 5-million Users' DNA With new Drug Partner
23andMe via NBC News

Moving From DNA to Drug Development Partnerships

Until now, 23andMe mainly stuck to DNA breakdowns, ancestry revelations, and genetic predispositions to certain illnesses based on your ancestry. That is, until GlaxoSmithKline — the London-based drug colossus — partnered with them.

They both want to develop new drugs, splitting profits and costs equally. That’s where the $300-million funding round comes in: it’s from GlaxoSmithKline.

In July of this year, Forbes stated that Anne Wojcicki’s net worth is probably around $440-million USD. She’s the founder of 23andMe, as well as the chief executive.

She told Forbes that the partnership would be “transformative” for 23andMe. Given that the once only genomics company is breaking into pharmaceutical development, she definitely is not wrong.

The company’s 5 million customers granted 23andMe significant information about a variety of genetic backgrounds, genomes, and DNA strands.

GlaxoSmithKline will more than likely gain access to that information in this partnership.

This partnership does provide a double-edged sword. On the one hand, information on the DNA and ancestral history of 5 million individuals will be a colossal gain for medical studies and the potential for future cures to debilitating diseases.

However, it does mean that the 5 million customers who willingly gave their genetic identity to 23 and me will now have their most intimate information shared with a third party without their consent.

In any case, the future direction of the company is yet to be seen.

Is it worth giving up your personal genetic information to help future generations?

First AI Web Content Optimization Platform Just for Writers

Found this article interesting?

Let Juliet Childers know how much you appreciate this article by clicking the heart icon and by sharing this article on social media.


Profile Image

Juliet Childers

Content Specialist and EDGY OG with a (mostly) healthy obsession with video games. She covers Industry buzz including VR/AR, content marketing, cybersecurity, AI, and many more.

Comments (0)
Most Recent most recent
You
share Scroll to top

Link Copied Successfully

Sign in

Sign in to access your personalized homepage, follow authors and topics you love, and clap for stories that matter to you.

Sign in with Google Sign in with Facebook

By using our site you agree to our privacy policy.